Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer

In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022.


Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

The study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to the only other treatment available for this condition. Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma.


Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and efficacy profile with paxalisib in this high unmet need disease.